Telomerase Activity in Malignant and Benign Renal Tumors

Objectives: An important characteristic of malignant cells is their unlimited replicative potential, their immortality. In conferring this immortality, the enzyme telomerase is believed to play a crucial role. The detection of telomerase activity provides new knowledge regarding the biologic growth behavior of tumors and offers new diagnostic and therapeutic tools. Methods: In the present study the sensitive TRAP assay (telomeric repeat amplification protocol) was used to examine 44 malignant renal tumors and 8 benign tumors of the kidney and 52 specimens of normal renal tissue for telomerase activity. Results: Telomerase activity was detected in 63% of tissue samples obtained from histologically confirmed renal cell carcinomas. In cases of renal cell carcinoma restricted to the kidney, telomerase activity was detected in 58%. In cases in which tumor growth has progressed beyond the limits of the organ, telomerase activity was found in 69%. This stage dependence, however, did not reach statistical significance. No correlation to tumor grading was observed. Telomerase activity was found less frequent in chromophobe renal cell carcinomas. Neither the 8 benign renal tumors (4 oncocytomas and 4 angiomyolipomas) nor the specimens of normal kidney showed any evidence of telomerase activity. Conclusions: The proportion of remarkable slow-growing renal cell carcinomas showing telomerase activity is less than in other malignancies and may correlate with biologic growth behavior. Possible explanations include the presence of an alternative pathway, called ALT (alternative lengthening of telomeres) and an association with the loss or presence of the telomerase suppressor on the short arm of chromosome 3. Prolonged follow-up will be of special interest to determine whether lack of telomerase activity predicts favorable outcome.

[1]  B. Wullich,et al.  Genetic changes and telomerase activity in human renal cell carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  A. Lindblom,et al.  Loss of heterozygosity at chromosome 3p correlates with telomerase activity in renal cell carcinoma. , 1998, International journal of oncology.

[3]  O. Yoshida,et al.  Low frequency of positive telomerase activity in a chromophobe subtype of renal cell carcinoma. , 1998, The Journal of urology.

[4]  R. Weinberg,et al.  hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization , 1997, Cell.

[5]  R. Reddel,et al.  The telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit. , 1997, Human molecular genetics.

[6]  E. K. Parkinson,et al.  The genetic basis of human keratinocyte immortalisation in squamous cell carcinoma development: the role of telomerase reactivation. , 1997, European journal of cancer.

[7]  R. Reddel,et al.  Telomere dynamics and telomerase activity in in vitro immortalised human cells. , 1997, European journal of cancer.

[8]  J. Shay,et al.  Multiple pathways for the regulation of telomerase activity. , 1997, European journal of cancer.

[9]  J. Shay,et al.  A survey of telomerase activity in human cancer. , 1997, European journal of cancer.

[10]  N. Kim,et al.  Clinical implications of telomerase in cancer. , 1997, European journal of cancer.

[11]  M. Oshimura,et al.  Multiple pathways to cellular senescence: role of telomerase repressors. , 1997, European journal of cancer.

[12]  A. Matsuura,et al.  TLP1: A Gene Encoding a Protein Component of Mammalian Telomerase Is a Novel Member of WD Repeats Family , 1997, Cell.

[13]  E. K. Parkinson,et al.  Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer , 1997, Oncogene.

[14]  June Corwin,et al.  Telomerase Catalytic Subunit Homologs from Fission Yeast and Human , 1997 .

[15]  H. Stein,et al.  Telomerase activity in bladder cancer, bladder washings and in urine. , 1996, International journal of oncology.

[16]  H. Kosmehl,et al.  Telomerase activity and telomere length in different areas of renal cell carcinoma. , 1996, International journal of oncology.

[17]  J. Shay,et al.  A nonradioactive, fluorescence-based telomeric repeat amplification protocol to detect and quantitate telomerase activity. , 1996, Trends in genetics : TIG.

[18]  J. Shay,et al.  Telomerase activity in human renal cell carcinoma. , 1996, Oncogene.

[19]  S. Semba,et al.  Molecular biological observations in gastric cancer. , 1996, Seminars in oncology.

[20]  D. Corey,et al.  Inhibition of human telomerase activity by peptide nucleic acids , 1996, Nature Biotechnology.

[21]  J. Shay,et al.  Detection of telomerase activity in malignant and nonmalignant skin conditions. , 1996, The Journal of investigative dermatology.

[22]  J. Shay,et al.  Telomerase activity in human cancer. , 1996, Current opinion in oncology.

[23]  M. Oshimura,et al.  Restoration of the Cellular Senescence Program and Repression of Telomerase by Human Chromosome 3 , 1995, Japanese journal of cancer research : Gann.

[24]  J. Shay,et al.  Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. , 1995, Nucleic acids research.

[25]  R. Reddel,et al.  Telomere elongation in immortal human cells without detectable telomerase activity. , 1995, The EMBO journal.

[26]  et al.,et al.  The RNA component of human telomerase , 1995, Science.

[27]  J. Shay,et al.  Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. , 1995, Cancer research.

[28]  B. Leber,et al.  Telomerase activity in normal leukocytes and in hematologic malignancies. , 1995, Blood.

[29]  Keiko Hiyama,et al.  Correlating telomerase activity levels with human neuroblastoma outcomes , 1995, Nature Medicine.

[30]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[31]  G. Roos,et al.  Telomere shortening in renal cell carcinoma. , 1994, Cancer research.

[32]  J. Brooks,et al.  Tumor suppressor gene allelic loss in human renal cancers. , 1993, The Journal of urology.

[33]  B. Gusterson,et al.  Are tumours immortal? , 1992, European journal of cancer.

[34]  G. Morin The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats , 1989, Cell.

[35]  L. S. Cram,et al.  A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[36]  W. Thoenes,et al.  Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. , 1986, Pathology, research and practice.

[37]  Carol W. Greider,et al.  Identification of a specific telomere terminal transferase activity in tetrahymena extracts , 1985, Cell.

[38]  A M Olovnikov,et al.  A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. , 1973, Journal of theoretical biology.

[39]  G. Murphy,et al.  A murine renal cell carcinoma. , 1973, Journal of the National Cancer Institute.

[40]  J. Watson Origin of concatemeric T7 DNA. , 1972, Nature: New biology.